干扰素β与丙种球蛋白治疗实验性周围神经病的机理研究  

Therapeutic mechanisms of interferon-15 and intravenous immunoglobulin for experimental peripheral neuropathy

作　　者：高玉兴[1] 李淑兰[1] 韩秀珍[1] 孙雁[1] 姚春美[1] 

机构地区：[1]山东省立医院小儿神经科,济南250021

出　　处：《中华儿科杂志》2007年第8期574-578,共5页Chinese Journal of Pediatrics

摘　　要：目的探讨干扰素β(IFN-β)和丙种球蛋白(IVIG)对空肠弯曲菌(CJ)脂多糖(LPS)诱导的免疫性周围神经病的治疗机理。方法健康 Wister 大鼠40只,体重205～230 g,用 CJ LPS 成功诱导出免疫神经病后,随机分为 IFN-β组、IVIG 组、IFN-β联合 IVIG 组和正常对照组。IFN-β组:每隔1 d,给予 IFN-β 1.3μg/kg 皮下注射,共6周。IVIG 组:每隔2周,静脉注射 IVIG400 mg/(kg·d),连续5 d,共2次。IFN-β和 IVIG 联合组:IFN-β和 IVIG 的给药时间分别同 IFN-β组和 IVIG 组。对照组:以 PBS 溶液(200μl/只)替代 IFN-β或 IVIG。分别于治疗前和治疗后第2、4、6周取血,用 ELISA方法检测血清中抗 GM_1 IgG、MMP-9和 TNF-α滴度,第6周取坐骨神经进行病理学检查和免疫组化检测坐骨神经上特异性 IgG 结合。结果 (1)3个治疗组治疗2周时,抗 GM_1 IgG、MMP-9和 TNF-α滴度与对照组比较差异无统计学意义(P>0.05)。(2)3个治疗组治疗4周时,抗 GM_1 IgG、MMP-9和TNF-α滴度明显低于对照组(P<0.01);3组之间抗 GM_1 IgG滴度比较差异无统计学意义(P>0.05);联合治疗组 MMP-9和 TNF-α水平低于单一治疗组(P<0.05)。(3)3个治疗组治疗6周时,抗 GM_1 IgG、MMP-9和 TNF-α滴度、神经原纤维病变率和神经上特异性 IgG 结合明显低于对照组(P<0.01);各指标联合治疗组明显低于单一治疗组(P<0.01)。结论 IFN-β和 IVIG 通过对特异性体液免疫和细胞免疫的同时抑制,达到对 CJLPS 诱导的免疫性周围神经病的治疗作用;IFN-β和 IVIG 联合应用疗效更佳。Objective To explore the therapeutic mechanisms of interferon-β （IFN-β） and intravenous immunoglobulin （IVIG） for experimental peripheral neuropathy induced by Campilobacter jejuni （Cj） lipopolysaccharide （LPS）. Method Forty healthy Wistar rats weighing 205-230 g were divided into IFN-β, IVIG, IFN-β plus IVIG and control groups. After the immune neuropathy was induced in the rats by Cj LPS, IFN-β （1.3 μg/kg） was given by subcutaneous injection to the rats every other day for 6 weeks; MG [400 mg/（kg·d）] was given to the rats for five days, every other week for two times and IFN-β [ 1.3 μg/（ kg·d）] and IVIG [400 mg/（ kg·d）] were given to the rats on the same days. Meanwhile, the control group was given PBS. The sera were collected in the 2nd, 4th and 6th week after therapy, the titers of anti- GM1 IgG , MMP-9 and TNF-α in sera of immunized rats were measured by ELISA; histological study of sciatic nerve was performed and IgG on sciatic nerve was detected by immunohistochemistry in the 6th week. Results （ 1 ） There were no significant differences in titers of anti-GM1 IgG, MMP-9 and TNF-α among the 3 therapeutic groups and control group after therapy for 2 weeks （ P 〉 0.05 ）. （2） The titers of anti- GM1 IgG, MMP-9 or TNF-α in the control group were much higher than those of the IFN-β group, the IVIG group or the IFN-β and IVIG group after therapy for 4 weeks （ P 〉 0. 01 ） and there were no significant differences in titers of antibody among the 3 therapeutic groups （P 〉 0. 05 ） ; the titers of MMP-9 or TNF-α in the IFN-β and IVIG group were lower than those of the IFN-β group or the IVIG group （ P 〈 0.05）. （3） The titers of anti-GM1 IgG, MMP-9 or TNF-α in the control group were much higher than those of the IFN-β group, the MG group or the IFN-β with IVIG group after therapy for 6 weeks （P 〉0. 01 ） ; the IFN-β with MG group had much lower levels of all indexes than the IFN-β group or the IVIG group （ P 〈 0. 01 ）.

关 键 词：干扰素-Β 免疫球蛋白类 静脉内 周围神经系统疾病 

分 类 号：R745.1[医药卫生—神经病学与精神病学]